All News
ACR20 – Day 1 Report
Friday was the first full day of scientific sessions at the 2020 Virtual ACR/ARP annual meeting. Here are my highlights from day one:
Read Article
Prelim. results: Immunogenicity of adjuvanted #HerpesZoster subunit #vaccine in #RheumatoidArthritis patients taking #JAKinhibitors
- Most RA pts on JAKi have sufficient antibody response to HZ vaccine
- Acceptable safety profile
Abs#1997 #ACR20 @RheumNow
https://t.co/8HWAIwOATD
Mrinalini Dey DrMiniDey ( View Tweet)
Dr Kaellmark reports on immunogenicity of adjuvant herpes zoster subunit vaccine in RA patients treated with JAKi. 40 RA patients and 20 controls. Satisfactory serological responses and tolerability seen. @rheumnow #ACR20 Abstr#1997 https://t.co/UlDe4NllU0
Richard Conway RichardPAConway ( View Tweet)
Deucravacitinib is a novel Tyrosine kinase 2 (TYK2) prev shown efficacy in psoriasis, now effective in PsA. PhII trial of 203 PsA patients showed wk 16 significant improvement in ACR20/50/70, enthesitis, SPARC scores. #ACR20 Abstr#L03 https://t.co/LGokmmlyrc
Dr. John Cush RheumNow ( View Tweet)
Dr Bergman reports on PROs in RCT of upadacitinib versus abatacept in bDMARD-IR RA patients. Greater improvement in PROs with upadacitinib especially in physical functioning, pain, and general health @rheumnow #ACR20 Abstr#1728 https://t.co/NWKrhYAfZn
Richard Conway RichardPAConway ( View Tweet)
SELECT-CHOICE on UPA vs ABA in RA in NEJM Oct 2020. How about PROs? UPA wins in phys fxn, pain, general health over ABA. Abst#1728 @RheumNow #ACR20. ABA better if a safety concern, but this is more evid to go for UPA
Eric Dein ejdein1 ( View Tweet)
@rheumnow #acr20 #absL03 RCDB PC ph2 trial TYK2i Deucravacitinib for PsA: ACR 20 at 16wk 6 mg 52.9% & 12 mg 62.7% vs PBO 31.8%. csDMARD & TNFi failure included. no serious infections, herpes zoster, opportunistic infections, or thrombotic events https://t.co/WVm4llPv5i
Olga Petryna DrPetryna ( View Tweet)
No need to stop Tofa w/the flu?
👉Posthoc analysis 7964 Tofa pts over 14-15 flu seasons reported similar flu rates compared to ADA, MTX, PCB.
👉Tofa cont. in 70% pts; 28.8% stopped; mean days to resolution similar.
Abstr#L04 #ACR20 @rheumnow #ACRBest
https://t.co/rZXKRVl7uK
k dao KDAO2011 ( View Tweet)
@RetamozoSole @RheumNow @Reumaclinic @MAS_Clinic @hospitalclinic #ACR20 Thanks for sharing! but our data show that patients under anti-Cytokine therapy in monotherapy at baseline (specifically anti-IL6 -IL12/23 and -IL17) or under JAKinh were ⬇️LESS likely to be admitted (OR 0.15; 95% CI 0.03-0.66; p=0.012)
📍Limitations: small number of pts https://t.co/zeLzrNLeDQ
Juan Camilo Sarmiento-Monroy jcsam25 ( View Tweet)
SELECT-PsA Phase 3, Placebo, Active controlled trial of Upadacitinib in PsA
1⃣UPA 15mg or 30mg - ⬆️PROs vs. Placebo thru 24wks
2⃣Similar improvement in UPA 15mg vs. 30mg
3⃣Both doses similar or > Adalimumab
@RheumNow #ACR20 Abs#1341 #ACRbest https://t.co/yu9IEX8tf0
Robert B Chao, MD doctorRBC ( View Tweet)
Network Meta-Analysis of JAK and TNF Inhib in 19 AS studies (3,654pts) showed best results with TNFi (golimumab and infliximab) but JAKs also appear to be effective option. #ACR20 Abstr#1357 #UTSW @AdelaCastro222 https://t.co/HnnPD6eXW5 https://t.co/Li30kkp3P1
Dr. John Cush RheumNow ( View Tweet)
#ACR20👀🔥🔥@AliDuarteMD Population epi revealed:
⭐️Markedly increased SLE incidence
⭐️Drastically increased SLE prevalence
Better epi saves 🫀, saves💰, informs better🧪🔬and💉🩺@RheumNow @LupusOrg @LupusResearch https://t.co/CTzJuB9DVk
Yu (Ray) Zuo RayZuoMD ( View Tweet)
UPA was efficacious in treating axial symptoms in pts with PsA. #ABS1372 #ACR20 @RheumNow https://t.co/ut6L0jM9WJ https://t.co/6H2N3ap6eI
Dr. Rachel Tate uptoTate ( View Tweet)
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort https://t.co/ZzhE0J7dOX #TOFA #TNFi TNFi does better with MTX Tofa less necessary
Peter Nash drpnash ( View Tweet)
EQUATOR2 52wk extension trial - Filgotinib on enthesitis in PsA pts
1️⃣Clinical resolution of enthesitis at 52wks 77% by LEI and SPARCC
2️⃣Pts who did not respond by wk 16➡️77% and 81% resolution enthesitis by LEI and SPARCC
@RheumNow #ACR20 Abs#0910 https://t.co/mCe32rrAcc
Robert B Chao, MD doctorRBC ( View Tweet)
Poll results are in... most chose upadacitinib followed by tofacitinib as their Jak-i of choice if insurance approval was not a factor in those that failed a bDMARD and remain on a cDMARD with high dz activity! @RheumNow @LCalabreseDO @ElaineHusniMD #ACR20 https://t.co/rl1nTqxzKg
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Australian study looking at clinical outcomes following in-class switching vs switching MOA. Rapid effect of IL-17i and JAKi with PsA rated highly. This study highlights ever-growing need for precision medicine based on domain. #ABS09003 #ACR20 @RheumNow https://t.co/7qKH6aw6f0
Dr. Rachel Tate uptoTate ( View Tweet)
What do you think? The great debate continues... leave your thoughts in the comment section below! #ACR20 @RheumNow @LCalabreseDO @CCalabreseDO https://t.co/KwQX0XoO93
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Concise, educational and useful table by @ArleneBravoMD presented by Dr. Arthur Kavanaugh in his PsA clinical trials update.
Beautiful organization of targeted therapy in multiple autoimmune diseases.
Bedside to Bench. @RheumNow #ACR20 https://t.co/PIvvsQWs0J
Robert B Chao, MD doctorRBC ( View Tweet)
This convinces me! #TNF inhibitors vs #JAKI
great debate at #ACR20 https://t.co/Xb8KkmDJ8f
KenWarringtonMD MdWarrington ( View Tweet)
